Kejriwal posted on X, "Prime Minister ji, do something at least. Why is the Prime Minister of 140 crore people so helpless in the end? Can't you handle anything at all?"
Rao also said that the move by the US government reflects a targeted approach towards India's growing economy and prosperous workforce abroad. "The foreign governments, like in America, are trying to target the Indian economy because it's growing, and targeting Indian people because they are
Gogoi further stated that the "draconian measure" was hurting not just the US, but also the biggest and brightest minds that powered the American innovation.
Highlighting the contributions of Telugu people in technological fields in US, Kavitha told ANI, "Telugu people have made contributions to the US in developing the country and making it a technologically sound country. Telugu software engineers and Telugu businessmen have made great contr
Samajwadi Party chief Akhilesh Yadav on Saturday slammed the Centre as the Trump administration imposed a USD 100,000 annual charge for H-1B visas and called foreign policy "weak".
Bikram Chabhal, president of AVIC, said Trump's decision to raise the H-1B visa fee to USD 100,000 will heavily impact Indians, who form 70% of holders. He warned companies may struggle to pay, but added India could benefit if skilled workers return home.
Former senior Indian diplomat Mahesh Sachdev on Saturday described US President Donald Trump's proclamation of imposing a USD 100,000 annual fee on H-1B visa applications as a "two-edged sword", warning that it could undermine America's IT innovation while significantly impacting Indian com
Congress leader Pawan Khera on Saturday criticised PM Modi's silence on Trump's executive order, which raised the fee for companies to sponsor H-1B applicants to $100,000.
Former diplomat KP Fabian criticised US President Donald Trump's order raising H-1B visa sponsorship fees to USD 100,000, calling it "an atrocity and unnecessary." He warned it would hurt Indians and the American economy, saying Trump was "keen on scoring a self-goal."
India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.